Headlines about Sangamo BioSciences (NASDAQ:SGMO) have been trending somewhat positive this week, according to Accern Sentiment. Accern rates the sentiment of media coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Sangamo BioSciences earned a daily sentiment score of 0.23 on Accern’s scale. Accern also gave news articles about the biopharmaceutical company an impact score of 20 out of 100, meaning that recent media coverage is very unlikely to have an impact on the stock’s share price in the near term.
Here are some of the news articles that may have effected Accern’s rankings:
- Sangamo Therapeutics Announces Closing Of Public Offering Of Common Stock And Exercise In Full Of Underwriters’ Option To Purchase Additional Shares Of Common Stock (finance.yahoo.com)
- Research Analysts Issue Forecasts for Sangamo BioSciences, Inc.’s Q2 2017 Earnings (SGMO) (americanbankingnews.com)
- Analysts Showing Optimistic Trends For Sangamo Biosciences Inc. (SGMO) (naijaoversabi.com)
- Sangamo Biosciences (SGMO) Plans Common Stock Offering – StreetInsider.com (streetinsider.com)
- Sangamo Therapeutics (SGMO) — Trending Stock Buzzer (cote-ivoire.com)
Shares of Sangamo BioSciences (NASDAQ:SGMO) traded down 2.14% during mid-day trading on Tuesday, hitting $9.15. The stock had a trading volume of 408,584 shares. Sangamo BioSciences has a 1-year low of $2.65 and a 1-year high of $9.50. The stock’s 50-day moving average is $6.93 and its 200-day moving average is $4.71. The firm’s market capitalization is $658.24 million.
Sangamo BioSciences (NASDAQ:SGMO) last posted its quarterly earnings data on Wednesday, May 10th. The biopharmaceutical company reported ($0.23) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.26) by $0.03. The company had revenue of $3.40 million for the quarter, compared to analyst estimates of $4.14 million. Sangamo BioSciences had a negative return on equity of 50.76% and a negative net margin of 380.44%. The firm’s quarterly revenue was down 12.8% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.23) earnings per share. Equities analysts expect that Sangamo BioSciences will post ($0.94) earnings per share for the current year.
A number of research firms have issued reports on SGMO. ValuEngine upgraded shares of Sangamo BioSciences from a “sell” rating to a “hold” rating in a research report on Thursday, June 15th. Wedbush restated a “neutral” rating and set a $4.00 target price on shares of Sangamo BioSciences in a research report on Wednesday, March 1st. Jefferies Group LLC restated a “buy” rating and set a $17.00 target price on shares of Sangamo BioSciences in a research report on Thursday, June 22nd. Cowen and Company restated a “buy” rating on shares of Sangamo BioSciences in a research report on Tuesday, February 28th. Finally, Piper Jaffray Companies restated a “neutral” rating and set a $5.00 target price on shares of Sangamo BioSciences in a research report on Tuesday, February 28th. Five research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. The company has an average rating of “Hold” and an average price target of $8.50.
ILLEGAL ACTIVITY NOTICE: “Sangamo BioSciences (SGMO) Given Media Impact Score of 0.23” was first published by sleekmoney and is the sole property of of sleekmoney. If you are accessing this piece of content on another site, it was copied illegally and reposted in violation of US and international copyright and trademark law. The original version of this piece of content can be viewed at https://sleekmoney.com/sangamo-biosciences-sgmo-given-media-impact-score-of-0-23/1943970.html.
About Sangamo BioSciences
Sangamo Therapeutics, Inc, formerly Sangamo BioSciences, Inc, is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy.
This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/sangamo-biosciences-sgmo-given-media-impact-score-of-0-23/1943970.html
Receive News & Ratings for Sangamo BioSciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo BioSciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.